基于真实世界实用性随机对照研究评价中医药序贯治疗类风湿关节炎的临床疗效

注册号:

Registration number:

ITMCTR2100005077

最近更新日期:

Date of Last Refreshed on:

2021-07-19

注册时间:

Date of Registration:

2021-07-19

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

基于真实世界实用性随机对照研究评价中医药序贯治疗类风湿关节炎的临床疗效

Public title:

Evaluation of the sequence of traditional Chinese medicine based on the practicality of the real world Clinical efficacy of treatment of Rheumatoid Arthritis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于真实世界实用性随机对照研究评价中医药序贯治疗类风湿关节炎的临床疗效

Scientific title:

Evaluation of the sequence of traditional Chinese medicine based on the practicality of the real world Clinical efficacy of treatment of Rheumatoid Arthritis

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2100048928 ; ChiMCTR2100005077

申请注册联系人:

谢志军

研究负责人:

谢志军

Applicant:

Xie Zhijun

Study leader:

Xie Zhijun

申请注册联系人电话:

Applicant telephone:

+86 571 86613587

研究负责人电话:

Study leader's telephone:

+86 571 86613587

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

xzj575@163.com

研究负责人电子邮件:

Study leader's E-mail:

xzj575@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

浙江省杭州市滨江区滨文路548号

研究负责人通讯地址:

浙江省杭州市滨江区滨文路548号

Applicant address:

548 Binwen Road, Binjing District, Hangzhou, Zhejiang, China

Study leader's address:

548 Binwen Road, Binjing District, Hangzhou, Zhejiang, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

浙江中医药大学

Applicant's institution:

ZHEJIANG CHINESE MEDICAL UNIVERSITY

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2020-KL-139-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

浙江中医药大学医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Zhejiang University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2019/7/16 0:00:00

伦理委员会联系人:

邵科盯

Contact Name of the ethic committee:

Shao Keding

伦理委员会联系地址:

浙江省杭州市滨江区滨文路548号

Contact Address of the ethic committee:

548 Binwen Road, Binjing District, Hangzhou, Zhejiang, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

浙江中医药大学

Primary sponsor:

ZHEJIANG CHINESE MEDICAL UNIVERSITY

研究实施负责(组长)单位地址:

浙江省杭州市滨江区滨文路548号

Primary sponsor's address:

548 Binwen Road, Binjing District, Hangzhou, Zhejiang, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

杭州

Country:

China

Province:

Zhejiang

City:

Hangzhou

单位(医院):

浙江中医药大学

具体地址:

滨江区滨文路548号

Institution
hospital:

ZHEJIANG CHINESE MEDICAL UNIVERSITY

Address:

548 Binwen Road, Binjiang District

经费或物资来源:

国家重点研发计划,编号2018YFC1705501

Source(s) of funding:

National Key R&D Program of China (2018YFC1705501)

研究疾病:

类风湿关节炎

研究疾病代码:

Target disease:

Rheumatoid Arthritis

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

采用真实世界的实用性随机对照临床试验,评价针对RA活动期和缓解期患者的中医药序贯治疗方案在改善关节炎、减缓关节畸形、提高生存质量及减少西药副作用方面的临床疗效,并评价中医序贯治疗方药的安全性。

Objectives of Study:

Using real-world practical randomized controlled clinical trials to evaluate the clinical efficacy of the sequential treatment of traditional Chinese medicine for patients with RA in the active and remission phases in improving arthritis, reducing joint deformities, improving the quality of life and reducing the side effects of western medicine, and evaluate The safety of sequential treatment prescriptions of traditional Chinese medicine.

药物成份或治疗方案详述:

中医药治疗方案根据病情处于活动期和缓解期的不同,采用序贯治疗方案结合母方案的设计(活动期和缓解期的基本方中均以核心处处作为母方案,即苍术10 g、虎杖15 g、当归10 g、炒薏苡仁18 g、炙甘草6 g)。 1.活动期:祛风解毒、化湿通络中医药方案联合西医方案治疗: (1)中医药基本方:蜈蚣1条、金银花15 g、炒白芍9 g、苍术10 g、虎杖15 g、当归10 g、炒薏苡仁18 g、炙甘草6 g。 (2)中医药辨证加味: 热偏盛:加知母15 g; 寒偏盛:加桂枝15g; 腰痛:加杜仲12 g; 腰以上痛加:羌活9 g; 腰以下痛加:独活9 g 中药均从指定厂家采购,保留厂家的中药质量检测(包括产地,性状,种属、指纹图谱检测、杂质等),并保留样品,提交各味中药颗粒含量国家药典标准的质量检测报告。 2.缓解期:补益肝肾、化痰通络中医药方案联合西医方案治疗: (1)中医药基本方:桑寄生12 g、熟地黄12 g、白僵蚕9 g、乌梢蛇(酒制)9 g、菟丝子12 g、苍术10 g、虎杖15 g、当归10 g、炒薏苡仁18 g、炙甘草6 g。 (2)中医药辨证加味: 热偏盛:加知母15 g; 寒偏盛:加桂枝15g; 腰痛:加杜仲12 g; 腰以上痛加:羌活9 g; 腰以下痛加:独活9 g

Description for medicine or protocol of treatment in detail:

纳入标准:

1. 符合2010 年ACR/EULAR 的RA 分类标准; 2. 5.1>DAS28>3.2(入组时,RA患者病情处于活动期); 3. 符合脾虚兼湿毒瘀痹阻证的RA 患者; 4. 病程≤24 个月; 5. 18 岁~65 岁; 6. 患者知情并同意参加本研究。

Inclusion criteria

1. Meet the 2010 ACR/EULAR RA classification standard; 2. 5.1>DAS28>3.2 (at the time of enrollment, the RA patients were in active condition); 3. RA patients with syndrome of spleen deficiency and dampness toxin stasis obstruction; 4. Course of disease <= 24 months; 5. Aged 18 to 65 years; 6. The patient informed and agreed to participate in this study.

排除标准:

1. 有严重脏器病变者或精神类疾病者; 2. 对研究方案中涉及的药物过敏或有使用禁忌者。

Exclusion criteria:

1. Patients with severe organ disease or mental illness; 2. Those who are allergic to the drugs involved in the research protocol or have contraindications to their use.

研究实施时间:

Study execute time:

From 2021-07-01

To      2022-01-01

征募观察对象时间:

Recruiting time:

From 2021-07-20

To      2022-01-02

干预措施:

Interventions:

组别:

2组

样本量:

135

Group:

Group 2

Sample size:

干预措施:

西药

干预措施代码:

Intervention:

Western Medicine

Intervention code:

组别:

1组

样本量:

135

Group:

Group 1

Sample size:

干预措施:

中西医结合治疗

干预措施代码:

Intervention:

Integrated Chinese and Western Medicine Treatment

Intervention code:

样本总量 Total sample size : 270

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

浙江

市(区县):

杭州

Country:

China

Province:

Zhejiang

City:

Hangzhou

单位(医院):

浙江大学附属第二医院

单位级别:

三级甲等

Institution/hospital:

The Second Affiliated Hospital of Zhejiang University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

浙江

市(区县):

杭州

Country:

China

Province:

Zhejiang

City:

Hangzhou

单位(医院):

浙江大学附属邵逸夫医院

单位级别:

三级甲等

Institution/hospital:

Sir Run Run Shaw Hospital Affiliated to Zhejiang University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

浙江

市(区县):

杭州

Country:

China

Province:

Zhejiang

City:

Hangzhou

单位(医院):

杭州市中医院

单位级别:

三级甲等

Institution/hospital:

Hangzhou Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

浙江

市(区县):

杭州

Country:

China

Province:

Zhejiang

City:

Hangzhou

单位(医院):

浙江中医药大学附属第一医院

单位级别:

三级甲等

Institution/hospital:

The First Affiliated Hospital of Zhejiang Chinese Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广州中医药大学第一临床医学院

单位级别:

三级甲等

Institution/hospital:

The First Clinical Medical College of Guangzhou University of Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

云南

市(区县):

昆明

Country:

China

Province:

Yunnan

City:

Kunming

单位(医院):

云南省中医医院

单位级别:

三级甲等

Institution/hospital:

Yunnan Provincial Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市中医医院

单位级别:

三级甲等

Institution/hospital:

Shanghai Traditional Chinese Medicine Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院附属西苑医院

单位级别:

三级甲等

Institution/hospital:

Xiyuan Hospital Affiliated to China Academy of Chinese Medical Science

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院附属广安门医院

单位级别:

三级甲等

Institution/hospital:

Guang'anmen Hospital Affiliated to China Academy of Chinese Medical Science

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

安徽

市(区县):

合肥

Country:

China

Province:

Anhui

City:

Hefei

单位(医院):

安徽中医药大学第一附属医院

单位级别:

三级

Institution/hospital:

The First Affiliated Hospital of Anhui University of Chinese Medicine

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

浙江

市(区县):

杭州

Country:

China

Province:

Zhejiang

City:

Hangzhou

单位(医院):

浙江大学附属第一医院

单位级别:

三级甲等

Institution/hospital:

The First Affiliated Hospital of Zhejiang University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

浙江

市(区县):

杭州

Country:

China

Province:

Zhejiang

City:

Hangzhou

单位(医院):

浙江中医药大学附属第二医院

单位级别:

三级甲等

Institution/hospital:

The Second Affiliated Hospital of Zhejiang Chinese Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中日友好医院

单位级别:

三级甲等

Institution/hospital:

China-Japan Friendship Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京中医药大学东方医院

单位级别:

三级甲等

Institution/hospital:

Dongfang Hospital Affiliated to Beijing University of Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

浙江

市(区县):

杭州

Country:

China

Province:

Zhejiang

City:

Hangzhou

单位(医院):

浙江中医药大学附属第三医院

单位级别:

三级甲等

Institution/hospital:

The Third Affiliated Hospital of Zhejiang Chinese Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

不良事件发生率

指标类型:

次要指标

Outcome:

Incidence rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

类风湿关节炎病情活动度评价指数

指标类型:

主要指标

Outcome:

Rheumatoid arthritis disease activity evaluation index DAS28

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者自身病情的总体评估

指标类型:

次要指标

Outcome:

Overall assessment of the patient's own condition PGA

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

DAS28 低活动率

指标类型:

主要指标

Outcome:

DAS28 low activity rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

EULAR 反应标准

指标类型:

主要指标

Outcome:

EULAR response standard

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

改善率,ACR20/50/70 Improvement rate

指标类型:

次要指标

Outcome:

Improvement rate, ACR20/50/70 Improvement rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

安全性指标

指标类型:

次要指标

Outcome:

Safety index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

SDAI 缓解率

指标类型:

次要指标

Outcome:

SDAI remission rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

DAS28 缓解率

指标类型:

主要指标

Outcome:

DAS28 remission rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生活质量评分量表SF36

指标类型:

次要指标

Outcome:

Quality of life scale SF36

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

临床的疾病活动指数评分

指标类型:

次要指标

Outcome:

Clinical disease activity index score CDAI

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

关节超声评分

指标类型:

次要指标

Outcome:

Joint ultrasound score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

健康评估问卷残疾指数

指标类型:

次要指标

Outcome:

Health Assessment Questionnaire Disability Index HAQ-DI

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

简化的疾病活动指数评分

指标类型:

次要指标

Outcome:

Simplified disease activity index score SDAI

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医证候评分

指标类型:

次要指标

Outcome:

TCM syndrome score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

慢性疾病治疗的功能评估-疲劳

指标类型:

次要指标

Outcome:

Functional Assessment of Treatment of Chronic Diseases-Fatigue FACIT-F

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

关节Sharp评分

指标类型:

次要指标

Outcome:

Sharp—van der Heijde score, 关节超声评分 Joint ultrasound score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

CDAI 缓解率

指标类型:

次要指标

Outcome:

CDAI remission rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

医生对患者病情的总体评估

指标类型:

次要指标

Outcome:

Doctor's overall assessment of the patient's condition MDGA

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

粪便

组织:

Sample Name:

Stool

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

尿

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 65
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用多中心分层区组随机法。本试验采用区组随机法。以中心数分为9个中心(center),每个中心5个区组(block),每个区组长度为6(length)。通过 SAS软件产生多中心分层区组随机号,随机分配受试者进入中药组,甲氨喋呤组。每组患者均为135人。SAS参数如下:center:9;block:5;length:6,随机结果由项目承担单位保管。

Randomization Procedure (please state who generates the random number sequence and by what method):

Multicentre stratified block random method was used. Block random method was used in this experiment. According to the number of centers, it is divided into 9 centers, each center has 5 blocks, and the length of each block is 6. Subjects were randomly assigned to the traditional Chinese medicine gr

盲法:

Not stated

Blinding:

Not stated

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

lcblcjsystem.zcmu.edu.cn

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

lcblcjsystem.zcmu.edu.cn

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病历记录表、电子采集管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Medical records, electronic collection and management system

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统